Bluejay Q3: $7.4M Cash, Going Concern Reaffirmed, $10-14M Raise Still Needed
BJDX sits 42% above its 52-week low of $1.841 on light trading volume (0.1× avg).
Summary
Bluejay's Q3 10-Q shows $7.4 million of cash, a $6.3 million nine-month net loss, and a reaffirmed going concern warning, with $10-14 million of additional capital still needed by the end of fiscal 2027.
Key Events · Earnings and Guidance · BJDX
-
Q3 Net Loss Widens to $6.3M
Nine-month net loss was $6,255,097 versus $5,418,671 a year earlier, and the quarter alone lost $2,011,843. R&D rose to $3,366,212 from $2,460,304 on SYMON-II trial costs.
-
Cash of $7.4M, Runway to Q2 2027
Cash and equivalents were $7,379,983 at September 30, 2026 against current liabilities of $1,927,320. Management estimates this funds operations only through the second quarter of 2027.
-
Going Concern and Liquidation Risk
The filing states substantial doubt about the ability to continue as a going concern and warns that without financing the board could pursue a Chapter 7 liquidation in which shareholders could recoup little or nothing.
-
$10-14M Raise Still Required
Bluejay expects to need $10.0 million to $14.0 million of additional capital by the end of fiscal 2027 to fund commercialization and a planned 510(k) submission in the first half of 2027.
Analysis · BJDX · Industrial Applications And Services
Bluejay closed September with $7.4 million in cash against $1.9 million of current liabilities, yet the 10-Q reaffirms the going concern warning and states that cash only funds operations through the second quarter of 2027. To reach a 510(k) submission in the first half of 2027, the company still needs $10-14 million, and it warns that failure to raise could force a Chapter 7 liquidation. The nine-month net loss widened to $6.3 million from $5.4 million as R&D spending climbed on the SYMON-II sepsis trial. After the November 3 reverse split cut shares to 1.1 million, the filing flags that a close below $1.00 for 30 straight trading days would put the Nasdaq listing at risk, with no cure period available before the one-year anniversary of the January 2026 split.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BJDX was trading at $2.61 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $1.84 to $28.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.